Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288204 | 0.90 | SLC7A5 (0.52) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL10530419 | 0.90 | SLC7A5 (0.52) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL27932393 | 0.90 | SLC7A5 (0.52) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL3191865 | 0.86 | SLC7A5 (0.33) | SLC7A5 | |
| SCHEMBL28172100 | 0.86 | SLC7A5 (0.44) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL28065518 | 0.86 | SLC7A5 (0.44) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL17164620 | 0.84 | SLC7A5 (0.42) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL28019556 | 0.83 | SLC7A5 (0.46) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL28327922 | 0.83 | SLC7A5 (0.35) | SLC7A5DPP4DPP7 | |
| SCHEMBL10710883 | 0.83 | SLC7A5 (0.46) | SLC7A5DPP4FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190160188-A1 | Radiolabeled Alpha-Melanocyte Stimulating Hormone Hybrid Peptide for Melanoma Targeting | STC UNM (US) | 2019-05-30 | — | — | US | claimed |
| US-20190160188-A1 | Radiolabeled Alpha-Melanocyte Stimulating Hormone Hybrid Peptide for Melanoma Targeting | STC UNM (US) | 2019-05-30 | — | — | US | disclosed |
| US-10238758-B2 | Radiolabeled alpha-melanocyte stimulating hormone hybrid peptide for melanoma targeting | STC.UNM (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180273626-A1 | OMALIZUMAB RESISTANT IGE VARIANTS AND THEIR USE IN ANTI-IGE THERAPY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO UNIV (US) | 2018-09-27 | — | — | US | disclosed |
| US-9901559-B2 | Compositions comprising amino acids, with pro-angiogenic activity | DETERMINANTS OF METABOLISM RESEARCH LABORATORY S.R.L. (IT) | 2018-02-27 | — | — | US | disclosed |
| US-20170087259-A1 | RADIOLABELED ALPHA-MELANOCYTE STIMULATING HORMONE HYBRID PEPTIDE FOR MELANOMA TARGETING | STC UNM (US) | 2017-03-30 | — | — | US | disclosed |
| US-9463255-B1 | Radiolabeled alpha-melanocyte stimulating hormone hybrid peptide for melanoma targeting | STC.UNM (US) | 2016-10-11 | — | — | US | disclosed |
| US-20130085170-A1 | COMPOSITIONS COMPRISING AMINO ACIDS, WITH PRO-ANGIOGENIC ACTIVITY | PROFESSIONAL DIETETICS S.R.L. (IT) | 2013-04-04 | — | — | US | disclosed |
| EP-2296642-A1 | COMPOSITIONS COMPRISING AMINO ACIDS, WITH PRO-ANGIOGENIC ACTIVITY | Professional Dietetics S.r.l. (IT) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009147637-A1 | COMPOSITIONS COMPRISING AMINO ACIDS, WITH PRO-ANGIOGENIC ACTIVITY | PROFESSIONAL DIETETICS S.R.L. (IT) | 2009-12-10 | — | — | WO | disclosed |
| US-20040250313-A1 | Insecticidal proteins and synergistic combinations thereof | SYNGENTA LIMITED (GB) | 2004-12-09 | — | — | US | disclosed |
| EP-1399473-A2 | INSECTICIDAL PROTEINS AND SYNERGISTIC COMBINATIONS THEREOF | Syngenta Limited (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002098911-A2 | INSECTICIDAL PROTEINS AND SYNERGISTIC COMBINATIONS THEREOF | SYNGENTA LIMITED (GB) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160188-A1 | Radiolabeled Alpha-Melanocyte Stimulating Hormone Hybrid Peptide for Melanoma Targeting | MC1R, MC3R, MC4R | SLC7A5 416/4885DPP4 473/4885FAP 633/4885 |
| US-20170087259-A1 | RADIOLABELED ALPHA-MELANOCYTE STIMULATING HORMONE HYBRID PEPTIDE FOR MELANOMA TARGETING | MC1R, MC3R, MC4R | SLC7A5 416/4885DPP4 473/4885FAP 633/4885 |
| US-10238758-B2 | Radiolabeled alpha-melanocyte stimulating hormone hybrid peptide for melanoma targeting | MC1R, MC3R, MC4R | SLC7A5 416/4885DPP4 473/4885FAP 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.